Want to see CARL full AI Analyst Report?
CARL Stock Chart & Stats
$15.60
$0.65(6.02%)
At close: 4:00 PM EDT
$15.60
$0.65(6.02%)
Day’s Range― - ―
52-Week Range$8.50 - $17.23
Previous Close$11.45
Volume46.52K
Average Volume (3M)75.96K
Market Cap
$387.15M
Enterprise Value$214.83M
Total Cash (Recent Filing)$89.22M
Total Debt (Recent Filing)$21.92M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Nov 05, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding27,302,744
10 Day Avg. Volume52,967
30 Day Avg. Volume75,960
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.78
Price to Sales (P/S)3.48
P/FCF Ratio-5.93
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue3.39
Enterprise Value/Gross Profit4.43
Enterprise Value/Ebitda-8.92
Forecast
1Y Price Target
$19.67Price Target Upside26.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.45
Revenue Forecast (FY)$76.74M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue With Strong Gross MarginsFaster revenue growth combined with consistently high gross margins indicates solid product economics and increasing commercial traction. If sustained, this combination can provide more gross profit to fund expansion, support operating leverage, and strengthen the company’s competitive position in personalized spine surgery.
Modest Leverage Supports Financial FlexibilityRelatively modest leverage reduces the immediate burden of interest and debt repayment compared with a highly indebted business. This gives Carlsmed greater flexibility to invest in its platform and commercial growth, although the benefit depends on improving profitability and maintaining access to capital.
Stronger Leadership And Reaffirmed Growth OutlookAdding an experienced CFO while maintaining the full-year revenue outlook supports confidence in financial oversight and execution during a scaling phase. Reaffirmed guidance also indicates management continues to see demand and procedure expansion supporting near- to medium-term commercial growth.
Bears Say
Deep And Widening Net LossesLarge and increasing losses show that Carlsmed’s current operating cost structure absorbs most of the value created by revenue and gross profit. Without meaningful operating leverage, continued growth may not translate into earnings, limiting internal funding capacity and extending the path to sustainable profitability.
Persistent And Increasing Cash BurnOngoing negative operating and free cash flow means the business is not yet self-funding its operations or expansion. The increase in absolute cash burn during 2025 raises the importance of external financing and creates greater execution risk until revenue growth converts into durable positive cash generation.
Unstable Equity Base And Negative ReturnsThe sharp change from negative to positive equity suggests the balance sheet improvement may reflect significant financing or other structural changes rather than accumulated profitability. Negative return on equity reinforces that shareholder capital is not yet producing positive returns through the company’s operations.
Carlsmed, Inc. News
CARL FAQ
What was Carlsmed, Inc.’s price range in the past 12 months?
Carlsmed, Inc. lowest stock price was $8.50 and its highest was $17.23 in the past 12 months.
What is Carlsmed, Inc.’s market cap?
Carlsmed, Inc.’s market cap is $387.15M.
When is Carlsmed, Inc.’s upcoming earnings report date?
Carlsmed, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Carlsmed, Inc.’s earnings last quarter?
Carlsmed, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.006.
Is Carlsmed, Inc. overvalued?
According to Wall Street analysts Carlsmed, Inc.’s price is currently Undervalued.
Does Carlsmed, Inc. pay dividends?
Carlsmed, Inc. does not currently pay dividends.
What is Carlsmed, Inc.’s EPS estimate?
Carlsmed, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Carlsmed, Inc. have?
Carlsmed, Inc. has 27,302,744 shares outstanding.
What happened to Carlsmed, Inc.’s price movement after its last earnings report?
Carlsmed, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went up 1.032%.
Which hedge fund is a major shareholder of Carlsmed, Inc.?
Currently, no hedge funds are holding shares in CARL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Carlsmed, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (26.07% Upside)
$19.67 (26.07% Upside)
Blogger Sentiment
Bullish
CARL Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 23.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.18%
12-Months-Change
Fundamentals
Return on Equity
-38.06%
Trailing 12-Months
Asset Growth
121.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
CARL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: robust top-line growth (Q1 revenue +58%), significant surgeon adoption (+60% surgeon users YoY), production efficiencies (lead time cut >30%, gross margin +220 bps), compelling peer‑reviewed clinical outcomes (74% reduction in two-year revisions), and constructive reimbursement developments (NTAP renewal and proposed favorable CMS coding). Offsetting these positives are rising operating expenses (+61% YoY), deeper GAAP losses and negative adjusted EBITDA, and higher cash burn from operations. The company raised full-year revenue guidance and expects operating leverage as revenue scales, while some policy items remain preliminary. On balance, the business appears to be in a growth-investment phase with improving unit economics and strong market validation but elevated near-term losses as it invests to scale.View all CARL earnings summariesCARL Stock 12 Month Forecast
Average Price Target
$19.67
▲(26.07% Upside)
Technical Analysis
OneMedNet
―
Aclarion, Inc.
―
BullFrog AI Holdings, Inc.
―
Tempus AI, Inc. Class A
―
HeartFlow, Inc.
―
Ownership Overview
33.52% Insiders
6.12% Mutual Funds
0.07% Other Institutional Investors
57.68% Public Companies and
Individual Investors